Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2019

View Archived Issues

FDA clears Wellspring's IND for KRAS G12C inhibitor ARS-3248

FOX-115 improves endurance of motor performances in aged mice

Phase I trial explores use of CAR T-cell therapy targeting claudin18.2 in advanced solid tumors

Shanghai Fosun Pharmaceutical studies MEK inhibitor FCN-159 in advanced melanoma

Design of an ATP-competitive chemical inhibitor of spastin

BNTA promotes generation of extracellular matrix components and delays osteoarthritis progression

Engineering B cells may enable skipping the vaccine

Forcing a multitasker to focus

Boosting PTEN foils Myc

Takeda presents new data for TAK-831

Preliminary phase II results show improved function with apraglutide in short bowel syndrome

Mutations in a subunit of DNA polymerase alpha-primase underlie an X-linked intellectual disability

Somatic variants in PDGFRB gene are involved in the physiopathology of fusiform cerebral aneurysm

Japanese researchers patent RyR1 channel blockers

Phase II results of ExPEC4V vaccine against extraintestinal pathogenic E. coli in healthy adults

Phase I trials of mRNA vaccines against H10N8 and H7N9 influenza viruses confirm immunogenicity

U.S. researchers present TGFR inhibitors

Yumanity Therapeutics synthesizes new SCD1 and SCD5 inhibitors

Interim analysis of INTELLANCE-1 study of Depatux-M in GBM shows no survival benefit

Merck & Co. divulges new HCV inhibitors

Genentech describes RIPK1 inhibitors

FDA approves Gattex for pediatric patients with short bowel syndrome

Travoprost implant OTX-TIC safe, improves intraocular pressure in phase I trial

New phase II trial studies TQB-2450 in relapsed or refractory classical Hodgkin's lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...